To include your compound in the COVID-19 Resource Center, submit it here.

CPI-613: Phase I data

An ongoing, open-label, dose-escalation, U.S. Phase I trial in 5 evaluable patients showed that

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE